35.7% Below Target

The consensus Wall Street price target for THC is $259.5, representing 35.7% upside from the current price of $191.2. With 32 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

THC has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $259.5 implies 35.7% upside from current levels.

With a forward P/E of 10.6586x, THC trades at a relatively low valuation. The consensus target of $259.5 implies 35.7% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $288 for THC, while the most conservative target is $210. The consensus of $259.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $253 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

THC is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month THC stock forecast based on 32 Wall Street analysts shows a consensus price target of $259.5, with estimates ranging from $210 (bear case) to $288 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $192, with bear/bull scenarios of $121/$253.

Our quantitative valuation model calculates THC's fair value at $192 (base case), with a bear case of $121 and bull case of $253. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.

THC trades at a forward P/E ratio of 10.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are very optimistic on THC, with a "Buy" consensus rating and $259.5 price target (35.7% upside). 26 of 32 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

THC analyst price targets range from $210 to $288, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $259.5 consensus represents the middle ground. Our model's $121-$253 range provides an independent fundamental perspective.